AU4348893A - Neuropeptide y antagonists - Google Patents

Neuropeptide y antagonists

Info

Publication number
AU4348893A
AU4348893A AU43488/93A AU4348893A AU4348893A AU 4348893 A AU4348893 A AU 4348893A AU 43488/93 A AU43488/93 A AU 43488/93A AU 4348893 A AU4348893 A AU 4348893A AU 4348893 A AU4348893 A AU 4348893A
Authority
AU
Australia
Prior art keywords
pct
neuropeptide
peptides
sec
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU43488/93A
Other languages
English (en)
Inventor
Alejandro Jose Daniels
Dennis Heyer
Antonio Landavazo
Johann Jakob Leban
Andreas Spaltenstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of AU4348893A publication Critical patent/AU4348893A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU43488/93A 1992-06-20 1993-06-18 Neuropeptide y antagonists Abandoned AU4348893A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929213215A GB9213215D0 (en) 1992-06-20 1992-06-20 Peptides
GB9213215 1992-06-20
PCT/GB1993/001297 WO1994000486A1 (en) 1992-06-20 1993-06-18 Neuropeptide y antagonists

Publications (1)

Publication Number Publication Date
AU4348893A true AU4348893A (en) 1994-01-24

Family

ID=10717514

Family Applications (1)

Application Number Title Priority Date Filing Date
AU43488/93A Abandoned AU4348893A (en) 1992-06-20 1993-06-18 Neuropeptide y antagonists

Country Status (12)

Country Link
US (1) US5670482A (en:Method)
EP (1) EP0672055B1 (en:Method)
JP (1) JPH07508273A (en:Method)
AT (1) ATE184022T1 (en:Method)
AU (1) AU4348893A (en:Method)
CA (1) CA2138374A1 (en:Method)
DE (1) DE69326250D1 (en:Method)
GB (1) GB9213215D0 (en:Method)
IL (1) IL106060A (en:Method)
MX (1) MX9303694A (en:Method)
TW (1) TW279166B (en:Method)
WO (1) WO1994000486A1 (en:Method)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516653A (en) * 1993-12-28 1996-05-14 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof
US5545549A (en) 1994-02-03 1996-08-13 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
US5696093A (en) * 1994-10-28 1997-12-09 Crc For Biopharmaceutical Research Pty Limited Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5989920A (en) 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
WO1997034873A1 (fr) * 1996-03-21 1997-09-25 Banyu Pharmaceutical Co., Ltd. Derives d'aminopyridine
US6265215B1 (en) * 1996-09-13 2001-07-24 Ludwig Institute For Cancer Research Isolated peptides which complex with HLA-Cw16 and uses thereof
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
WO1998040356A1 (fr) * 1997-03-12 1998-09-17 Banyu Pharmaceutical Co., Ltd. Medicaments contenant des derives d'aminopyridine comme ingredient actif
US6713265B1 (en) 1997-06-04 2004-03-30 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
US6046167A (en) * 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
WO2000030674A1 (en) * 1998-11-26 2000-06-02 Ferring Bv Neuropeptide y y4 agents in the treatment of reproductive disorders
US20040053864A1 (en) * 2000-01-20 2004-03-18 Gerard Karsenty Methods and compositions for control of bone formation via modulation of neuropeptide y activity
AU2002348131A1 (en) 2001-12-05 2003-06-23 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of sympathetic tone
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
JP4806628B2 (ja) 2003-05-05 2011-11-02 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤
WO2005049027A2 (en) 2003-11-03 2005-06-02 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
KR101099206B1 (ko) 2004-02-05 2011-12-27 프로비오드룩 아게 신규한 글루타미닐 시클라제 저해제
AU2006235200A1 (en) * 2005-04-15 2006-10-19 Regenertech Pty Limited Use of Neuropeptide Y (NPY) and agonists and antagonists thereof for tissue regeneration
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
EA200901140A1 (ru) 2007-03-01 2010-04-30 Пробиодруг Аг Новое применение ингибиторов глутаминилциклазы
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
CA2714617A1 (en) 2008-03-06 2009-09-11 Banyu Pharmaceutical Co., Ltd. Alkylaminopyridine derivative
NZ598685A (en) 2009-09-11 2013-05-31 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
CA2789879A1 (en) * 2009-10-28 2011-05-19 Joyant Pharmaceuticals, Inc. Dimeric smac mimetics
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2545047B9 (en) 2010-03-10 2015-06-10 Probiodrug AG Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602019A (en) * 1983-04-22 1986-07-22 Warner-Lambert Company Indeno[1,2-c]pyridazin-3-one derivatives useful as cardiotonic and antihypertensive agents
US5128332A (en) * 1984-10-23 1992-07-07 Perstorp Ab Method of treating cardiovascular diseases using inositoltrisphosphate
US5330979A (en) * 1984-10-23 1994-07-19 Perstorp Ab Method of treating renal disorders with inositoltriphosphate
US4891357A (en) * 1985-02-11 1990-01-02 University Of Florida Methods and compositions for stimulation of appetite
US4897445A (en) * 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
JPS646294A (en) * 1987-02-09 1989-01-10 Ajinomoto Kk Novel peptide derivative
US4839343A (en) * 1987-03-13 1989-06-13 Debiopharm, S.A. Preparation containing hexatriacontapeptides and methods of use
US6255067B1 (en) * 1987-09-15 2001-07-03 The Johns Hopkins University cDNA encoding peptidyl-glycine alpha-amidating monooxygenase (PAM)
DE3811193A1 (de) * 1988-04-01 1989-10-19 Boehringer Ingelheim Kg Neue peptide, verfahren zu ihrer herstellung und diese peptide enthaltende pharmazeutische zusammensetzungen
DE3813592A1 (de) * 1988-04-22 1989-11-02 Hoechst Ag Monoklonale antikoerper gegen das neuropeptid y, verfahren zu ihrer herstellung sowie ihre verwendung
US5328899A (en) * 1988-07-15 1994-07-12 The Salk Institute For Biological Studies NPY peptide analogs
ZA896376B (en) * 1988-08-26 1990-05-30 Merrell Dow Pharma Neuropeptide y agonists
ZA896374B (en) * 1988-08-26 1990-05-30 Merrell Dow Pharma Neuropeptide y antagonists
SE9002278L (sv) * 1990-06-28 1991-12-29 Perstorp Ab Anvaendning av inositoltrisfosfat foer framstaellning av ett laekemedel

Also Published As

Publication number Publication date
WO1994000486A1 (en) 1994-01-06
ATE184022T1 (de) 1999-09-15
DE69326250D1 (de) 1999-10-07
EP0672055B1 (en) 1999-09-01
MX9303694A (es) 1994-05-31
GB9213215D0 (en) 1992-08-05
EP0672055A1 (en) 1995-09-20
TW279166B (en:Method) 1996-06-21
IL106060A (en) 1998-10-30
US5670482A (en) 1997-09-23
IL106060A0 (en) 1993-10-20
CA2138374A1 (en) 1994-01-06
JPH07508273A (ja) 1995-09-14

Similar Documents

Publication Publication Date Title
AU4348893A (en) Neuropeptide y antagonists
GR3022510T3 (en) Lyospheres comprising gonadotropin
ATE185548T1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
IL112112A0 (en) Peptide derivatives and pharmaceutical compositions containing them
IL124674A0 (en) Piperazine derivatives pharmaceutical compositions containing the same and use thereof
SG55184A1 (en) New imidazopyridines
ZA98214B (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
AU7067594A (en) A stabilised phenylalanine ammonia lyase
IL117209A (en) 1-aryl-2-acylamino-ethane compounds and pharmaceutical compositions containing them
HUT67963A (en) Benzodiazepine derivatives as cck-receptor antagonits and pharmaceutical compositions containing them
SE9101838D0 (sv) Novel peptides and their use
MY125854A (en) Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
AU4706293A (en) Therapeutic use of phosphoryl-l-serine-n-acyl-sphingosine
AP9801182A0 (en) Endothelin receptor antagonists.
TW371661B (en) Novel intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
ATE141248T1 (de) Neue bis-phenyl-hexene
GR1002385B (el) Καθαρη μορφη στρεπτογραμινων, παρασκευη αυτης και φαρμακευτικες συνθεσεις που την περιεχουν.
AU5696194A (en) Methylbutoxy-propionitriles and their use as perfumes
ZA936605B (en) Optically active hydroquinine 1-(3-aminophenyl)-ethanesulphonate and its preparation and use
JO1711B1 (en) Therapeutic agents